[go: up one dir, main page]

BR0211181A - Formulação vacinal - Google Patents

Formulação vacinal

Info

Publication number
BR0211181A
BR0211181A BR0211181-0A BR0211181A BR0211181A BR 0211181 A BR0211181 A BR 0211181A BR 0211181 A BR0211181 A BR 0211181A BR 0211181 A BR0211181 A BR 0211181A
Authority
BR
Brazil
Prior art keywords
components
formulation
immune response
formulations
enhancing
Prior art date
Application number
BR0211181-0A
Other languages
English (en)
Inventor
Santiago Due As Carrera
Juan Morales Grillo
Liz Alvarez-Lajonchere Po Leon
Alexis Musacchio Lasa
Rolando Pajon Feyt
Ariel Vi A Rodriguez
Julio C Alvarez Obregon
Nelson Acosta Rivero
Gillian Martinez Donato
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of BR0211181A publication Critical patent/BR0211181A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"FORMULAçãO VACINAL". Formulação de antígenos vacinais, que contém como componentes principais: a) um ou vários ADN que expressam uma ou várias proteínas no indivíduo imunizado e b) um antígeno viral, em proporções adequadas. A novidade da invenção e proporcionada pelo efeito potencializador exercido por pelo menos um dos componentes sobre a resposta imunológica gerada contra o outro. Desenvolvimento de novas formulações, minimizando o número de componentes capazes de ampliar e potencializar o espectro de resposta imunológica contra diferentes entidades patogênicas e gerar vacinas combinadas contra entidades patogênicas. Estas formulações podem ser aplicadas na indústria farmacêutica para uso profilático e/ou terapêutico em humanos.
BR0211181-0A 2001-07-16 2002-07-12 Formulação vacinal BR0211181A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20010171A CU23244A1 (es) 2001-07-16 2001-07-16 Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
PCT/CU2002/000005 WO2003007986A2 (es) 2001-07-16 2002-07-12 Formulacion vacunal potenciada por la combinacion de un adn con un antigeno

Publications (1)

Publication Number Publication Date
BR0211181A true BR0211181A (pt) 2004-08-10

Family

ID=40091632

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211181-0A BR0211181A (pt) 2001-07-16 2002-07-12 Formulação vacinal

Country Status (16)

Country Link
US (2) US20040234543A1 (pt)
EP (1) EP1417973B1 (pt)
JP (1) JP4217611B2 (pt)
KR (1) KR100905249B1 (pt)
CN (1) CN1241644C (pt)
AR (1) AR034771A1 (pt)
AU (1) AU2002325783B2 (pt)
BR (1) BR0211181A (pt)
CA (1) CA2453260C (pt)
CU (1) CU23244A1 (pt)
ES (1) ES2393546T3 (pt)
MX (1) MXPA04000431A (pt)
MY (1) MY134885A (pt)
RU (1) RU2294212C2 (pt)
WO (1) WO2003007986A2 (pt)
ZA (1) ZA200400286B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23496A1 (es) * 2004-09-03 2010-02-23 Ct Ingenieria Genetica Biotech Composición vacunal contra el virus de la hepatitis c
EP1844142B1 (en) 2005-01-20 2015-08-12 Nature Technology Corporation Vectors and methods for genetic immunization
US9109012B2 (en) * 2007-05-29 2015-08-18 Nature Technology Corporation Vectors and method for genetic immunization
CN104830789A (zh) * 2015-05-05 2015-08-12 杨光华 基于hcv1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU642942B2 (en) * 1989-12-18 1993-11-04 Wellcome Foundation Limited, The Viral agent
EP0461863A1 (en) * 1990-06-12 1991-12-18 Immuno Japan Inc. Oligonucleotide primers, and their application for high-fidelity detection of non-A, non-B hepatitis virus
US7070790B1 (en) * 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US6689757B1 (en) * 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
CU22642A1 (es) * 1996-12-12 2000-12-22 Ct Ingenieria Genetica Biotech Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso
CN1044092C (zh) * 1997-02-26 1999-07-14 上海医科大学 抗原－抗体－重组dna复合型疫苗
FR2760367B1 (fr) * 1997-03-06 1999-04-30 Pasteur Merieux Serums Vacc Composition vaccinale destinee a la prevention ou au traitement des hepatites c
ES2328536T3 (es) * 1997-05-06 2009-11-13 Novartis Vaccines And Diagnostics, Inc. Produccion intracelular de polipeptido e2 truncado de la hepatitis c.
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
GB9726555D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
DE19915178A1 (de) * 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
US7329408B2 (en) * 1999-12-01 2008-02-12 Novartis Vaccines And Diagnostics, Inc. Eliciting HCV-specific antibodies

Also Published As

Publication number Publication date
US20040234543A1 (en) 2004-11-25
CA2453260C (en) 2013-03-19
WO2003007986A3 (es) 2004-03-04
MXPA04000431A (es) 2004-03-18
MY134885A (en) 2007-12-31
US8691234B2 (en) 2014-04-08
RU2294212C2 (ru) 2007-02-27
ES2393546T3 (es) 2012-12-26
CN1529616A (zh) 2004-09-15
RU2004104357A (ru) 2005-07-10
ZA200400286B (en) 2004-10-04
EP1417973B1 (en) 2012-08-29
CU23244A1 (es) 2007-10-17
WO2003007986A2 (es) 2003-01-30
EP1417973A2 (en) 2004-05-12
JP2004537552A (ja) 2004-12-16
AR034771A1 (es) 2004-03-17
AU2002325783B2 (en) 2006-08-17
CN1241644C (zh) 2006-02-15
JP4217611B2 (ja) 2009-02-04
KR20040028924A (ko) 2004-04-03
US20100316669A1 (en) 2010-12-16
CA2453260A1 (en) 2003-01-30
KR100905249B1 (ko) 2009-06-29
WO2003007986A8 (es) 2004-04-29

Similar Documents

Publication Publication Date Title
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
DK1326636T3 (da) Vaccinesammensætning
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
CY1113078T1 (el) Συνθεση πολυσθενους εμβολιου
CY1118521T1 (el) Συνθεση εμβολιου και μεθοδος χρησης αυτου
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
NO991524L (no) Vaksiner
BR0114393A (pt) Uso de uma preparação de vìrus envelopado dividido, método para produzir uma formulação de vacina intranasal, uso de uma preparação de vacina de vìrus envolopado dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por vìrus envelopado
BR0014281A (pt) Vacina contra vìrus de gripe intranasal
CY1114243T1 (el) Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
EP1326633A4 (en) COMPOSITION WITH IMMUNOGENIC MICROPARTICLES
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
BR0114786A (pt) Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
ATE381323T1 (de) Pharmazeutische zusammensetzungen enthaltend flavonoide und menthol
CY1108147T1 (el) Εμβολιο κατα των σεξουαλικως μεταδιδομενων νοσων
DK0588578T3 (da) Immunogener
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
EP1301208A4 (en) Vaccine
BR0211181A (pt) Formulação vacinal
BR9916893A (pt) Tratamento
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE. PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2342 DE 24/11/2015.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]